(1) For any cannabis product that a cannabis processing facility processes or produces and for any raw cannabis that the facility packages, the facility shall: (a) label the cannabis or cannabis product with a label that: (i) clearly and unambiguously states that the cannabis product or package contains cannabis; (ii) clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol, and any known cannabinoid that is greater than 1% of the total cannabinoids contained in the cannabis or cannabis product as determined under Subsection 4-41a-701(4); (iii) has a unique identification number that: (A) is connected to the inventory control system; and (B) identifies the unique cannabis product manufacturing process the cannabis processing facility used to manufacture the cannabis product; (iv) identifies the cannabinoid extraction process that the cannabis processing facility used to create the cannabis product; (v) does not display an image, word, or phrase that the facility knows or should know appeals to children; and (vi) discloses each active or potentially active ingredient, in order of prominence, and possible allergen; and (b) package the raw cannabis or cannabis product in a medicinal dosage form in a container that: (i) is tamper evident and tamper resistant; (ii) does not appeal to children; (iii) does not mimic a candy container; (iv) complies with child-resistant effectiveness standards that the United States Consumer Product Safety Commission establishes; (v) includes a warning label that states: (A) for a container labeled on or after January 1, 2024, "WARNING: Cannabis has intoxicating effects, may be addictive, and may increase risk of mental illness. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a recommending medical provider."; or (B) for a container labeled on or after January 1, 2026, "WARNING: Cannabis use by pregnant or breastfeeding women, may result in fetal injury, preterm birth, or developmental problems for the child. Cannabis may be addictive and may increase risk of mental illness. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a recommending medical provider."; and (vi) for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or after May 3, 2023, includes a warning label that states: (A) "WARNING: Vaping of cannabis-derived products has been associated with lung injury."; and (B) "WARNING: Inhalation of cannabis smoke has been associated with lung injury.". (2) (a) Except as provided in Subsection (2)(b), to ensure that a cannabis product that a cannabis processing facility processes or produces has a medical rather than recreational disposition, the facility may not produce or process a product whose logo, product name, or brand name includes terms related to recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganja," "Mary Jane," "high," "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank," "doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust," "bong," "budtender," "dab," "blaze," "toke," or "420." (b) A product name may contain the word "hash." (3) For any cannabis or cannabis product that the cannabis processing facility processes into a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape, the facility shall: (a) ensure that the label described in Subsection (1)(a) does not contain a photograph or other image of the content of the container; and (b) include on the label described in Subsection (1)(a) a warning about the risks of over- consumption. (4) For any cannabis product that contains an artificially derived cannabinoid, the cannabis processing facility shall ensure that the label clearly: (a) identifies each artificially derived cannabinoid; and (b) identifies that each artificially derived cannabinoid is an artificially derived cannabinoid. (5) (a) A cannabis processor may not distribute medical cannabis with a label, logo, brand name, or in packaging if the label, logo, brand name, or packaging has not been pre-approved by the department. (b) If the department has approved a label or packaging, a cannabis processor may change the approved label or packaging and use the changed label or packaging for use with another medical cannabis product without obtaining the department's approval if: (i) the label or packaging complies with the requirements of this chapter and rules made under this chapter; (ii) the only change to the label and packaging are changes to one or more of the following: (A) flavor information; (B) terpene information; or (C) cultivar information; and (iii) no other changes were made to the label or package including graphics, fonts, sizing, or colors. (6) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the department: (a) shall make rules to establish: (i) a standard labeling format that: (A) complies with the requirements of this section; and (B) ensures inclusion of a pharmacy label; and (ii) additional requirements on packaging for cannabis and cannabis products to ensure safety and product quality; (b) may make rules to further define standards regarding images, words, phrases, or containers that may appeal to children under Subsection (1)(a)(v) or (1)(b)(ii); and (c) may make rules to regulate the use of common terms describing a potential physiological effect on medical cannabis labels.
‹ Prev All Utah sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.